Search research articles
Contact Us
Filters
Showing results (1-10 of 174) with videos related to
Page
of 18
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)
|
May 25, 2007
Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis
Giovanni Monteleone, Flavio Caprioli
Inflammatory Bowel Diseases
|
February 19, 2026
The long game in ulcerative colitis: mirikizumab's four-year outcomes
Daniele Noviello, Flavio Caprioli
Inflammatory Bowel Diseases
|
September 26, 2008
Why are molecular mechanisms of immune activation important in IBD?
Giovanni Monteleone, Flavio Caprioli
Clinical Science (London, England : 1979)
|
March 31, 2010
T-cell-directed therapies in inflammatory bowel diseases
Giovanni Monteleone, Flavio Caprioli
The American Journal of Gastroenterology
|
November 11, 2024
Response to Wei-Zhen Tang et al
Gabriele Dragoni, Tommaso Innocenti, Flavio Caprioli
Expert Opinion on Investigational Drugs
|
June 28, 2013
Investigational cytokine-targeted therapies for ulcerative colitis
Giovanni Monteleone, Francesco Pallone, Flavio Caprioli
Gastroenterology
|
June 21, 2022
Environmental Protective and Risk Factors in an At-Risk Population of Subsequent Crohn's Disease
Daniele Noviello, Federica Facciotti, Flavio Caprioli
Journal of Crohn'S & Colitis
|
December 22, 2010
Th17 immune response in IBD: A new pathogenic mechanism
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Inflammation & Allergy Drug Targets
|
December 28, 2010
Cytokine therapies in Crohn's disease: where are we now and where should we go?
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Inflammatory Bowel Diseases
|
September 13, 2011
Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with crohn's disease
Chiara Viganò, Alessandra Losco, Flavio Caprioli, et al.
Page
of 18
Search research articles
Search
Showing results (1-10 of 174) with videos related to
Sort By:
Page
of 18
Current Opinion in Investigational Drugs (London, England : 2000)
|
May 25, 2007
Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis
Giovanni Monteleone, Flavio Caprioli
Inflammatory Bowel Diseases
|
February 19, 2026
The long game in ulcerative colitis: mirikizumab's four-year outcomes
Daniele Noviello, Flavio Caprioli
Inflammatory Bowel Diseases
|
September 26, 2008
Why are molecular mechanisms of immune activation important in IBD?
Giovanni Monteleone, Flavio Caprioli
Clinical Science (London, England : 1979)
|
March 31, 2010
T-cell-directed therapies in inflammatory bowel diseases
Giovanni Monteleone, Flavio Caprioli
The American Journal of Gastroenterology
|
November 11, 2024
Response to Wei-Zhen Tang et al
Gabriele Dragoni, Tommaso Innocenti, Flavio Caprioli
Expert Opinion on Investigational Drugs
|
June 28, 2013
Investigational cytokine-targeted therapies for ulcerative colitis
Giovanni Monteleone, Francesco Pallone, Flavio Caprioli
Gastroenterology
|
June 21, 2022
Environmental Protective and Risk Factors in an At-Risk Population of Subsequent Crohn's Disease
Daniele Noviello, Federica Facciotti, Flavio Caprioli
Journal of Crohn'S & Colitis
|
December 22, 2010
Th17 immune response in IBD: A new pathogenic mechanism
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Inflammation & Allergy Drug Targets
|
December 28, 2010
Cytokine therapies in Crohn's disease: where are we now and where should we go?
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Inflammatory Bowel Diseases
|
September 13, 2011
Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with crohn's disease
Chiara Viganò, Alessandra Losco, Flavio Caprioli, et al.
Page
of 18